戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  the gold standard for the treatment of PCO (Posterior Capsule Opacification).
2 , cystoid macular oedema (CMO), cataract and posterior capsule opacification.
3 nt, cystoid macular oedema, glare, halos and posterior capsule opacification.
4 an effective capsular bend as a deterrent to posterior capsule opacification.
5 ng mechanism for the aberrant cell growth in posterior capsule opacification.
6  pressure spikes, cystoid macular edema, and posterior capsule opacification.
7 and could be important in the development of posterior capsule opacification.
8 practical for use in longitudinal studies of posterior capsule opacification.
9 mmunotoxin may be effective in prevention of posterior capsule opacification.
10 e, and effective measure in the treatment of posterior capsule opacification.
11 d Pande et al. for precise quantification of posterior-capsule opacification.
12 y (0.9%), cataracts (3.6%), intraocular lens posterior capsule opacification (1.8%) and a posterior c
13         Postoperative complications included posterior capsule opacification (50.9%), posterior synec
14 ally valuable in prevention and treatment of posterior capsule opacification, a dreaded complication
15 tion (between piggyback intraocular lenses), posterior capsule opacification and lens epithelial cell
16  and pharmacologic methods); 2) treatment of posterior capsule opacification; and 3) characteristics
17 how resistant an intraocular lens will be to posterior capsule opacification as a consequence of rege
18 ept that sharp optic edges markedly decrease posterior capsule opacification as compared with round-e
19                                              Posterior-capsule opacification, by far the most common
20 d with lower rates of clinically significant posterior capsule opacification compared to treatment wi
21                                              Posterior capsule opacification developed in 11 eyes (57
22                                              Posterior capsule opacification developed in 14 eyes (34
23                                Evaluation of Posterior Capsule Opacification (EPCO) image analysis so
24 d with retroillumination using evaluation of posterior capsule opacification (EPCO) software.
25 stance visual acuity (CDVA), IOL centration, posterior capsule opacification, glaucoma, and retinal c
26 rban residency and were found in 60.4%, with posterior capsule opacification in 29.6% and posterior c
27 ecial interest are techniques for inhibiting posterior capsule opacification in pediatric patients by
28 d strength, which may decrease resistance to posterior capsule opacification in the face of a regener
29 sterior capsulorhexis is required to inhibit posterior-capsule opacification in pediatric patients; w
30                                              Posterior capsule opacification is a frequent postoperat
31                                              Posterior capsule opacification is also potentially solv
32                                              Posterior capsule opacification is an ongoing cellular r
33                                              Posterior capsule opacification is the most frequent lat
34                                              Posterior capsule opacification occurred in 66 eyes (82.
35 ll changes in the percentage area covered by posterior capsule opacification over time.
36 cantly higher rates of hypotony (p = 0.043), posterior capsule opacification (p = 0.047), and surgica
37 I(2) = 0%; n = 2 studies, 161 participants), posterior capsule opacification (P = 0.46; I(2) = 0%; n
38                                              Posterior capsule opacification (PCO) after cataract sur
39 le is known about the long-term incidence of posterior capsule opacification (PCO) after cataract sur
40          To objectively assess the long-term posterior capsule opacification (PCO) and neodymium-dope
41                                              Posterior capsule opacification (PCO) arises because of
42 provements in intraocular lens (IOL) design, posterior capsule opacification (PCO) arising from lens
43                   The fibrotic lens disorder posterior capsule opacification (PCO) develops in millio
44 ic IOLs' susceptibility to calcification and posterior capsule opacification (PCO) formation.
45          This resilient growth gives rise to posterior capsule opacification (PCO) in a significant p
46 antification of After-Cataract [AQUA II]) of posterior capsule opacification (PCO) in high-resolution
47                                              Posterior capsule opacification (PCO) is a complication
48                                              Posterior capsule opacification (PCO) is the most common
49                                              Posterior capsule opacification (PCO) is the most common
50 ct surgery is common, routine and effective, posterior capsule opacification (PCO) occurs in 30-50% o
51 tients gradually develop the complication of posterior capsule opacification (PCO) or secondary catar
52 dy were to determine the 5-year incidence of posterior capsule opacification (PCO) requiring Nd:YAG l
53 utive pseudophakic patients with symptomatic posterior capsule opacification (PCO) underwent Nd:YAG l
54 DVA), subjective refraction, IOL centration, posterior capsule opacification (PCO), and investigators
55 oped yttrium aluminum garnet capsulotomy for posterior capsule opacification (PCO), and visual acuity
56 ts due to a wound-healing response, known as posterior capsule opacification (PCO), following catarac
57           We describe a patient with massive posterior capsule opacification (PCO), i.e. Elschnig's P
58 ptic edge using an in vitro culture model of posterior capsule opacification (PCO).
59 s lenticular migration, thus contributing to posterior capsule opacification (PCO).
60 anti-TGF-beta2 antibody in a rodent model of posterior capsule opacification (PCO).
61 srupting complication of cataract surgery is posterior capsule opacification (PCO; secondary cataract
62 re instrumental in reducing the incidence of posterior capsule opacification, (PCO, secondary catarac
63  the eye this can cause blindness because of posterior capsule opacification, proliferative vitroreti
64 ion, allowing for a more rapid assessment of posterior capsule opacification resistance.
65 ge design appreciably improves resistance to posterior capsule opacification, significant factors rem
66 med and analyzed for PCO using Evaluation of Posterior Capsule Opacification software.
67       This review addresses 1) inhibition of posterior capsule opacification (surgical techniques, in
68 active lens exchange suggest higher rates of posterior capsule opacification than with standard catar
69                In 25% of pseudophakic cases, posterior capsule opacification was noted.
70 th and angle width in pseudophakic eyes with posterior capsule opacification were measured with anter